索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]马越峰,赵宵翰,张莹,等.抗肿瘤药物对心血管损伤的研究进展[J].国际心血管病杂志,2018,03:149-152.
点击复制

抗肿瘤药物对心血管损伤的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年03期
页码:
149-152
栏目:
综述
出版日期:
2018-05-25

文章信息/Info

Title:
-
作者:
马越峰; 赵宵翰; 张莹; 王潞
241001 芜湖,皖南医学院第一附属医院弋矶山医院肿瘤内科
Author(s):
-
关键词:
肿瘤;  化疗;  心血管损伤
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.03.007
文献标识码:
-
摘要:
传统和新型化疗药物均可引起心血管损伤。不同化疗药物引起心血管损伤的机制、表现形式、预后均不相同。新型检测手段可早期发现心血管损伤。早预防、早发现、早治疗可减轻或恢复心血管损伤。
Abstract:
-

参考文献/References

[1] Abe J, Martin JF, Yeh, et al. The future of onco-cardiology: we are not just 'side effect hunters'[J]. Circ Res, 2016, 119(8):896-899.
[2] Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1[J]. J Am Coll Cardiol, 2017, 70(20):2536-2551.
[3] Ichikawa Y, Zemljic-Harpf AE, Zhang Z, et al. Modulation of caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure in rabbits[J]. PLoS One, 2017, 12(5):e0177660.
[4] Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy[J]. Circulation, 2015, 131(22):1981-1988.
[5] O'hare M, Sharma A, Murphy K, et al. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity[J]. Expert Rev Cardiovasc Ther, 2015, 13(5):511-518.
[6] Tang GH, Acuna SA, Sevick L, et al. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single 'real-world' setting[J]. Med Oncol, 2017, 34(9):154.
[7] Maharsy W, Aries A, Mansour O, et al. Ageing is a risk factor in imatinib mesylate cardiotoxicity[J]. Eur J Heart Fail, 2014, 16(4):367-376.
[8] Fradley MG, Pinilla-Ibarz J. Arrhythmic complications of tyrosine kinase inhibitors[J]. Future Cardiol, 2015, 11(4):395-399.
[9] Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis[J]. PLoS One, 2012, 7(2):e30353.
[10] Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med, 2013, 369(6):507-516.
[11] Byrd JC, Brown JR, O'brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia[J]. N Engl J Med, 2014, 371(3):213-223.
[12] Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2[J]. J Am Coll Cardiol, 2017, 70(20):2552-2565.
[13] Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer[J]. J Am Coll Cardiol, 2014, 63(10):945-953.
[14] Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7):621-630.
[15] Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib(E7080)in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment[J]. Cancer, 2015, 121(16):2749-2756.
[16] Hanchate LP, Sharma SR, Madyalkar S. Cisplatin induced acute myocardial infarction and dyslipidemia[J]. J Clin Diagn Res, 2017, 11(6):OD05-OD07.
[17] a Dzaye OD, Cleator S, Nihoyannopoulos P. Acute coronary artery thrombosis and vasospasm following capecitabine in conjunction with oxaliplatin treatment for cancer[J]. BMJ Case Rep, 2014,22:2014
[18] Dechant C, Baur M, Böck R, et al. Acute reversible heart failure caused by coronary vasoconstriction due to continuous 5-fluorouracil combination chemotherapy[J]. Case Rep Oncol, 2012, 5(2):296-301.
[19] Roy A, Khanna N, Senguttuvan NB. Rituximab-vincristine chemotherapy-induced acute anterior wall myocardial infarction with cardiogenic shock[J]. Tex Heart Inst J, 2014, 41(1):80-82.
[20] Yusuf SW, Daraban N, Abbasi N, et al. Treatment and outcomes of acute coronary syndrome in the cancer population[J]. Clin Cardiol, 2012, 35(7):443-450.
[21] Oyakawa T, Iida K, Kusuhara M, et al. Chemotherapy-induced cardiomyopathy caused by Pemetrexed[J]. Invest New Drugs, 2018, 36(1):147-150.
[22] Coen M, Rigamonti F, Roth A, et al. Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature[J]. BMC Cancer, 2017, 17(1):394.
[23] Munoz E, Iliescu G, Vejpongsa P, et al. Takotsubo stress cardiomyopathy: 'good News' in cancer patients?[J]. J Am Coll Cardiol, 2016, 68(10):1143-1144.
[24] Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging, 2014, 15(10):1063-1093.
[25] Thavendiranathan P, Poulin F, Lim KD, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review[J]. J Am Coll Cardiol, 2014, 63(25 Pt A):2751-2768.
[26] Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab[J]. Circ Cardiovasc Imaging, 2012, 5(5):596-603.
[27] Negishi K, Negishi T, Haluska BA, et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection[J]. Eur Heart J Cardiovasc Imaging, 2014, 15(3):324-331.
[28] Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies:the OVERCOME trial(preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)[J]. J Am Coll Cardiol, 2013, 61(23):2355-2362.

备注/Memo

备注/Memo:
通信作者:王潞,Email:lucyyjs@163.com
更新日期/Last Update: 2018-06-01